Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Rating of “Moderate Buy” from Analysts
Beam Therapeutics INC (NASDAQ: BEAM) has been assigned a rating of "Moderate Buy" by the nine analysts following the company, ...
Beam Therapeutics INC (NASDAQ: BEAM) has been assigned a rating of "Moderate Buy" by the nine analysts following the company, ...
Terry-Ann Burrell, the Chief Financial Officer for Beam Therapeutics Inc. (NASDAQ: BEAM), disclosed on January 18 that she had sold ...
DISCLAIMER
Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
The Best Stocks, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.
Categories
Best Stocks to buy now
Crypto
Dow Jones Today
Pre-IPO and Startups
Tech stocks
Utility Stocks
Data and Tools
Stock Forecast
Dow Jones Today
© 2023 Best Stocks